Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
出版年份 2019 全文链接
标题
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
作者
关键词
-
出版物
Gastric Cancer
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-14
DOI
10.1007/s10120-019-00970-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status
- (2018) Lei Wang et al. Cancer Medicine
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
- (2018) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
- (2018) Seyoung Seo et al. Gastric Cancer
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma
- (2017) Eiji Oki et al. ONCOLOGY
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)
- (2016) Gastric Cancer
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-positive gastric cancer
- (2013) Narikazu Boku Gastric Cancer
- Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer
- (2012) Yung-Jue Bang JOURNAL OF CLINICAL GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started